Erwinaze for patients with
Acute Lymphoblastic Leukemia (ALL)

Acute lymphoblastic leukemia (ALL) is a common childhood cancer and is also (more rarely) found in adolescents and adults. With timely diagnosis and initiation of intensive treatment regimens, many patients – particularly children – achieve remission and cure^1,2.

This website provides information about ALL and how it is treated, and about Erwinaze (asparaginase Erwinia chrysanthemi) Full prescribing information can be found by clicking here – a recently approved asparaginase therapy which can be used as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with ALL who have developed hypersensitivity to native or pegylated Escherichia coli (E.coli)-derived asparaginases.

Erwinaze™ Indication

Erwinaze (asparaginase Erwinia chrysanthemi) is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase

CONTRAINDICATIONS: Hx of serious hypersensitivity to Erwinaze, including anaphylaxis; Hx of serious pancreatitis, thrombosis or hemorrhage with prior L-asparaginase therapy.

WARNINGS AND PRECAUTIONS: Discontinue if serious hypersensitivity, including anaphylaxis, OR severe or hemorrhagic pancreatitis occur. Monitor glucose (intolerance may not be reversible); With thrombosis and hemorrhage: discontinue until resolved. Use in pregnant women only if clearly needed. Do not use in lactating women.

COMMON (≥ 1%) ADVERSE REACTIONS: Serious hypersensitivity, including anaphylaxis, pancreatitis, abnormal transaminases, coagulation abnormalities, nausea, vomiting, and hyperglycemia.

Please see full Prescribing Information.

This site is only intended for residents of the United States.